Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $11.8571.

REPL has been the topic of several research analyst reports. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research note on Friday, August 7th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the company from $11.00 to $17.00 in a report on Tuesday, August 4th. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th.

Replimune Group Price Performance

REPL stock opened at $14.77 on Monday. The stock’s 50 day moving average price is $11.25 and its 200 day moving average price is $8.06. The firm has a market cap of $1.39 billion, a P/E ratio of -4.69 and a beta of 0.88. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. Replimune Group has a 1 year low of $1.50 and a 1 year high of $15.70.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). On average, sell-side analysts expect that Replimune Group will post -2.78 earnings per share for the current fiscal year.

Insider Buying and Selling at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Konstantinos Xynos sold 11,447 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the transaction, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. This trade represents a 4.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 91,124 shares of company stock worth $1,149,244. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently modified their holdings of REPL. International Assets Investment Management LLC purchased a new stake in shares of Replimune Group during the 4th quarter valued at about $29,000. Russell Investments Group Ltd. lifted its position in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after purchasing an additional 7,569 shares in the last quarter. CWM LLC grew its holdings in Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after purchasing an additional 2,886 shares in the last quarter. Essential Partners LLC lifted its holdings in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after buying an additional 6,873 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.